Ozempic vs Metformin: How the Two Diabetes Medicines Differ, and Why They Are Often Combined

The pharmacist slid two bags across the counter: a bottle of white tablets a grandmother would recognize, and a slim pen that did not exist a decade ago. The man collecting them asked the question that, as of September 2026, is climbing search charts faster than almost any other diabetes query: why do I need both? Interest in ozempic vs metformin has surged since United States diabetes guidelines stopped treating metformin as the automatic first step for everyone, and since semaglutide gained a formal approval in early 2025 for protecting kidneys in people with type 2 diabetes. Social media did the rest, with viral posts calling metformin outdated.

The posts are wrong, but the question underneath them is a good one. These two medicines were born in different centuries, act on different organs and carry different evidence. Understanding the contrast explains why so many prescriptions now carry both names on the same page.

Why ozempic vs metformin is the question of the moment

For roughly twenty years the recipe for a new type 2 diabetes diagnosis was simple: lifestyle changes plus metformin, then add something else if blood sugar stayed high. Metformin earned that spot honestly. It is inexpensive to produce, taken by mouth, does not cause weight gain and has outcome data stretching back to the 1990s.

Then a new class arrived. Glucagon-like peptide-1 receptor agonists, usually shortened to GLP-1 agonists, are medicines that copy a hormone the gut releases after eating. Semaglutide, sold as Ozempic for diabetes, became the best known of them because it did something older diabetes drugs rarely did: it produced visible weight loss and, in randomised trials, fewer heart attacks, strokes and kidney complications.

Two things pushed the comparison into everyday conversation. The American Diabetes Association now says that people with type 2 diabetes who already have cardiovascular disease, heart failure or chronic kidney disease should be offered a GLP-1 agonist or a related class with proven organ protection, whether or not they take metformin. At the same time, millions of people started semaglutide for weight management and wondered why their relatives with diabetes were still swallowing the old tablet.

The honest answer is that the two medicines are not rivals in the way the search phrase implies. One is a foundation, the other is an upgrade for particular goals, and for many people the right plan contains both. The sections that follow set out how each works, what the trials actually measured, where the side-effect profiles diverge and when the pairing makes sense.

What changed recently

Three dated developments explain the current spike in attention, and each is traceable in the references at the end of this article.

First, kidney protection. In May 2024 the FLOW trial, a randomised study of more than 3,500 adults with type 2 diabetes and chronic kidney disease, reported that semaglutide cut the combined risk of kidney failure, a large fall in kidney function or death from kidney or heart causes by about 24 percent compared with placebo. On January 28, 2025, the United States Food and Drug Administration added that use to the Ozempic label. MedlinePlus and Mayo Clinic drug pages now list reducing the risk of worsening kidney disease alongside blood sugar control and cardiovascular risk reduction.

Second, guidelines. The American Diabetes Association’s Standards of Care, updated each December, continued a shift that began in 2022: metformin remains a reasonable first choice for many, but it is no longer described as the mandatory starting point for people whose heart or kidneys are already affected. In those groups, medicines with proven organ benefit take priority.

Third, the end of the compounding era. The FDA declared the semaglutide shortage resolved in February 2025 and, after short grace periods, stopped permitting pharmacies to produce copies under shortage rules. Compounded semaglutide is not an approved product, has not been tested in the trials described here and is not something to obtain or use on your own. Anyone who used a compounded version and now has diabetes questions should raise them with a prescriber.

Metformin, by contrast, had no headline moment. Its evidence base simply kept being cited, including in the same guideline that moved it off center stage.

How metformin works in the body

Metformin belongs to a family called biguanides, a group of medicines derived from a compound first found in the French lilac plant. It has been prescribed in Europe since the late 1950s and in the United States since 1995, which gives it one of the longest safety records of any diabetes drug still in daily use.

Its main action is on the liver. In type 2 diabetes the liver keeps releasing glucose even when blood sugar is already high, especially overnight, which is why many people wake up with elevated readings. Metformin dampens that release. It also makes muscle and fat cells slightly more responsive to insulin, the hormone that moves glucose out of the blood and into cells, a property described as improving insulin sensitivity.

Two things metformin does not do matter just as much. It does not force the pancreas to pump out more insulin, so on its own it very rarely causes hypoglycemia, the medical term for blood sugar dropping too low. It also does not promote weight gain, which several older diabetes tablets do. In the Diabetes Prevention Program, a randomised trial of more than 3,000 adults at high risk, metformin reduced progression to diabetes by 31 percent over about three years and produced a modest average weight loss of around 2 kilograms.

The typical effect on hemoglobin A1c, the three-month average blood sugar measure, is a fall of roughly 1 to 1.5 percentage points when metformin is the only medicine. That is a meaningful change: every one-point reduction in A1c has been linked in observational data to fewer small-vessel complications of the eyes, kidneys and nerves.

Metformin is taken as a daily tablet, usually with food to reduce stomach upset. How it is started and adjusted is a decision for the prescriber, who will check kidney function first because the drug leaves the body through the kidneys.

How Ozempic (semaglutide) works in the body

Semaglutide is a laboratory-made molecule that resembles GLP-1, a hormone released by the small intestine within minutes of a meal. The natural hormone is broken down in the bloodstream in a few minutes; semaglutide is engineered to resist that breakdown and bind to blood proteins, which is why one injection lasts a week.

Its effects play out in four places at once. In the pancreas it increases insulin release, but only when glucose is high, so the risk of hypoglycemia stays low unless it is combined with insulin or a sulfonylurea. It also suppresses glucagon, the hormone that tells the liver to release stored sugar. In the stomach it slows emptying, which flattens the spike in blood sugar after eating. In the brain it acts on appetite centers, reducing hunger and, as many users describe it, quieting constant thoughts about food.

That last effect is the source of the weight loss. In the SUSTAIN program of randomised trials in type 2 diabetes, semaglutide lowered A1c by about 1.5 to 1.8 percentage points and reduced body weight by several kilograms more than comparator medicines over 30 to 56 weeks. Trials of the same molecule in weight-management programs showed larger losses, discussed later.

Semaglutide also comes as a daily tablet under a different brand name, and the same molecule is marketed separately for obesity. The label for Ozempic itself covers type 2 diabetes, cardiovascular risk reduction in adults with diabetes and established heart disease, and, since 2025, reducing the risk of kidney disease progression in adults with diabetes and chronic kidney disease.

The injection is given under the skin of the abdomen, thigh or upper arm once a week. The starting level, pace of increase and target are set by the prescriber and tailored to how the digestive system tolerates it.

Ozempic vs metformin at a glance

A side-by-side table makes the differences easier to hold in mind. The figures are typical ranges reported in randomised trials and summarized by MedlinePlus, Mayo Clinic and Cleveland Clinic; individual responses vary widely.

Feature	Metformin	Ozempic (semaglutide)
Drug class	Biguanide	GLP-1 receptor agonist
How taken	Daily tablet with food	Once-weekly injection under the skin
Main site of action	Liver, muscle	Pancreas, stomach, brain
Typical A1c reduction alone	About 1 to 1.5 points	About 1.5 to 1.8 points
Effect on weight	Neutral to about 2 kg loss	Several kg loss; around 10 percent of body weight in weight-focused trials
Hypoglycemia risk alone	Very low	Low
Proven heart benefit in trials	Suggestive (UKPDS subgroup, 1998)	Yes (SUSTAIN-6, 2016)
Proven kidney benefit in trials	No dedicated trial	Yes (FLOW, 2024)
Most common side effects	Diarrhea, nausea, metallic taste	Nausea, vomiting, constipation
Rare serious concerns	Lactic acidosis, vitamin B12 deficiency	Pancreatitis, gallbladder disease, thyroid tumor warning from animal studies
Years in clinical use	Since late 1950s (US since 1995)	Since 2017

Two patterns stand out. Semaglutide wins on the size of the glucose and weight effect and on hard outcome evidence for the heart and kidneys. Metformin wins on simplicity, tolerability for most people and the sheer length of its track record. Neither column is empty, which is exactly why the two are so often written on the same prescription.

Is Ozempic better than metformin for blood sugar control?

Measured purely by how far A1c falls, semaglutide is the more powerful medicine. Across the SUSTAIN trials it lowered A1c more than every comparator it was tested against, including a dipeptidyl peptidase-4 inhibitor, a sulfonylurea, basal insulin and another GLP-1 agonist. In the trial that enrolled people who had never taken a diabetes medicine, roughly three-quarters reached an A1c below 7 percent, the target many guidelines use.

Here is the catch for anyone trying to settle ozempic vs metformin with a single number: there is no large randomised trial that pits the two against each other head to head as first treatments. Most semaglutide trials recruited people who were already taking metformin and simply added the injection on top. So the comparison relies on indirect evidence, which is weaker than a direct test.

That indirect evidence still points one way. Metformin’s typical reduction is roughly a point to a point and a half; semaglutide’s is somewhat larger. Both effects shrink in people whose starting A1c is only mildly raised, because there is less room to fall.

Power is not the only measure that matters. Many people with newly diagnosed diabetes and an A1c just above the threshold reach their target on metformin alone, and a daily tablet with few side effects is easier to live with than weekly injections. Guidelines therefore reserve the stronger medicine for situations where it adds something beyond glucose: established heart or kidney disease, a need for substantial weight loss or an A1c well above target that metformin alone is unlikely to reach.

Whether semaglutide is better in a specific case depends on which goal is being chased. For glucose alone it is stronger; for the whole person, the answer is a conversation with the prescriber, not a leaderboard.

Metformin vs semaglutide weight loss: what the trials show

Weight is where the two medicines separate most clearly, and where the viral comparisons are closest to being right.

Metformin’s effect is real but small. In the Diabetes Prevention Program, participants on metformin lost about 2 kilograms on average over the first years, and that modest loss persisted in the follow-up study. For a medicine whose main job is glucose, weight neutrality is a bonus rather than a purpose.

Semaglutide’s effect is of a different order. In the SUSTAIN diabetes trials, people taking it lost roughly 4 to 6 kilograms more than those on comparator drugs. In a 68-week randomised trial of the same molecule at a higher weight-management level in adults with type 2 diabetes, average weight loss was close to 10 percent of starting body weight, compared with about 3 percent on placebo. People with diabetes tend to lose somewhat less than people without it, a pattern seen across the GLP-1 class.

Mechanism explains the gap. Metformin nudges metabolism; semaglutide changes appetite. People describe feeling full after smaller portions and losing interest in snacking, and brain imaging studies suggest reduced activation in reward regions when food is shown.

Two cautions belong here. First, the weight-management level of semaglutide is marketed under a separate brand with its own label; Ozempic itself is approved for diabetes, and using it purely for weight loss in someone without diabetes is a decision for a clinician, not something to pursue independently. Second, in extension studies, people who stopped semaglutide regained a large share of the weight within a year, which is why clinicians frame it as long-term treatment for a chronic condition rather than a short course.

Metformin will not deliver dramatic weight loss, and no honest comparison should imply otherwise. What it will do is avoid the weight gain some other glucose-lowering tablets cause.

Heart and kidney protection: where the evidence diverges

Lowering blood sugar is a means to an end. The outcomes that change lives are heart attacks, strokes, kidney failure and premature death, and here the two medicines stand on very different evidence.

Metformin’s claim rests mostly on the United Kingdom Prospective Diabetes Study, a randomised trial published in 1998. Among a subgroup of 342 overweight participants assigned to metformin, diabetes-related deaths fell by 42 percent and heart attacks by 39 percent compared with diet alone over about ten years. The findings were striking but came from a small group inside a larger trial, and later studies have been less consistent. Most reviewers describe metformin’s cardiovascular benefit as probable but not firmly proven by modern standards.

Semaglutide has dedicated outcome trials. SUSTAIN-6, published in 2016, randomised about 3,300 adults with type 2 diabetes at high cardiovascular risk and found a 26 percent relative reduction in the combined rate of cardiovascular death, non-fatal heart attack and non-fatal stroke over roughly two years. The FLOW trial in 2024 showed a 24 percent relative reduction in major kidney outcomes and also fewer cardiovascular deaths. A trial of the same molecule in people with obesity but without diabetes, reported in late 2023, found a 20 percent relative reduction in major cardiovascular events.

Relative reductions sound larger than they feel in daily life. In FLOW, the absolute difference was roughly five fewer major kidney events per 100 people over three years. That is a meaningful benefit, and it is also why guidelines target these medicines at people whose baseline risk is high enough for the absolute gain to matter.

The kidney point also cuts the other way for metformin. Because it is cleared by the kidneys, prescribers reduce or stop it when kidney function falls below certain thresholds. Semaglutide does not depend on the kidneys for clearance, which is one reason it has become central in diabetic kidney disease.

Side effects compared: stomach, nerves, gallbladder and more

Both medicines announce themselves through the digestive tract, but in different ways and with different timelines.

Metformin most often causes diarrhea, nausea, cramping and a metallic taste. Around a quarter of people notice some of this early on; for most it fades within weeks, and taking the tablet with meals or using an extended-release form, as directed by the prescriber, reduces it. Long-term use lowers vitamin B12 absorption, and the Diabetes Prevention Program follow-up found measurably more B12 deficiency in the metformin group after about a decade, so periodic blood checks are standard. Lactic acidosis, a dangerous buildup of acid in the blood, is the rare serious risk; it occurs in only a handful of cases per 100,000 person-years and almost always in people with significantly impaired kidneys, severe infection, heavy alcohol use or during contrast dye procedures.

Semaglutide’s hallmark is nausea, reported by roughly 15 to 20 percent of trial participants, along with vomiting, constipation and diarrhea. These cluster around increases in the amount given and usually ease over weeks. Less common but important are gallstones and gallbladder inflammation, pancreatitis, and dehydration from persistent vomiting that can strain the kidneys. The label carries a warning about thyroid C-cell tumors seen in rodent studies; a link in humans has not been established, but the medicine is avoided in people with a personal or family history of medullary thyroid cancer or a related genetic syndrome. Observational reports in 2024 raised a possible association with a rare optic nerve stroke; regulators have reviewed the signal and describe the absolute risk as very low, and research continues.

Hypoglycemia is uncommon with either medicine alone but becomes a real possibility when either is combined with insulin or sulfonylureas, which is why prescribers often adjust those drugs when adding semaglutide.

Can you take Ozempic and metformin together?

Yes, and the combination is one of the most common pairings in modern diabetes care. Far from being a sign that one medicine has failed, taking both usually reflects a deliberate strategy.

The logic is mechanical. Metformin works mostly on the liver and on insulin sensitivity; semaglutide works on the pancreas, the stomach and appetite. Because they act on different parts of the glucose system, their effects add up rather than overlap, and neither one blunts the other. Most of the SUSTAIN trials enrolled people already taking metformin and added semaglutide, so the safety and benefit data for the pair are, in effect, the main data for semaglutide itself.

The combination also carries a low risk of hypoglycemia, because neither medicine forces insulin release when glucose is normal. That contrasts with pairing either drug with a sulfonylurea or insulin, where low blood sugar becomes a genuine concern.

Guidelines reflect this. The American Diabetes Association describes adding a GLP-1 agonist to metformin as a standard step when A1c remains above target, and recommends the GLP-1 agonist regardless of metformin in people with established heart or kidney disease. Many clinicians keep metformin in place when they add semaglutide because it continues to contribute glucose lowering at very low cost in side effects, and because stopping a well-tolerated medicine without reason rarely helps.

Digestive side effects can stack, since both medicines can cause nausea or diarrhea. Prescribers often manage this by keeping metformin steady and introducing semaglutide gradually. Anyone struggling with persistent stomach symptoms on the pair should report it rather than quietly dropping a tablet; the prescriber may adjust one medicine while preserving the benefits of the other.

Switching from metformin to Ozempic: what that decision involves

Searches for switching from metformin to Ozempic have grown alongside the viral posts, and the phrase deserves careful handling. A switch means stopping one medicine and starting another. For many people what is actually recommended is an addition, not a replacement.

There are legitimate reasons a prescriber might stop metformin. Kidney function may have declined to a level where it is no longer appropriate. Digestive side effects may never have settled. Vitamin B12 deficiency may have become difficult to manage. In those cases semaglutide can take over the glucose-lowering role, often with a larger effect.

There are equally legitimate reasons to keep it. Metformin is well tolerated by most people who have been on it for years, it adds glucose lowering, and some observational studies associate it with lower rates of certain cancers and slower cognitive decline. Those observational findings are not proof, and a large randomised trial testing metformin for healthy aging has been proposed but not completed, so they should not drive decisions on their own. They do illustrate that the older medicine is not simply obsolete.

The decision belongs to the treating clinician, who will weigh kidney function, A1c, weight, heart and kidney history, other medicines and personal preference about injections. Stopping metformin on your own because a social media post declared it outdated can lead to a sharp rise in blood sugar within days, and starting semaglutide without medical supervision is unsafe and, in the case of compounded or online-sourced products, not sanctioned by regulators.

If a switch is agreed, expect monitoring. Blood sugar is checked more often during the transition, and the first weeks on semaglutide are when nausea is most likely, so prescribers usually schedule a review within the first couple of months.

What the evidence actually says, graded by strength

Not every claim in this comparison rests on the same footing. Grading the evidence shows where confidence is justified and where it is borrowed.

Strongest, from large randomised trials: semaglutide lowers A1c and body weight more than placebo and more than several active comparators; it reduces major cardiovascular events in people with type 2 diabetes and established heart disease (SUSTAIN-6); it reduces major kidney outcomes in people with diabetes and chronic kidney disease (FLOW). Metformin reduces progression from prediabetes to diabetes (Diabetes Prevention Program) and lowers A1c compared with diet alone (UKPDS and many smaller trials). The two medicines can be safely combined, since the combination was the background for most semaglutide trials.

Moderate, from smaller or older randomised data: metformin’s reduction in heart attacks and death, which comes from a 342-person UKPDS subgroup and has not been confirmed by a dedicated modern outcome trial. Semaglutide’s superiority over metformin as a first medicine, which is inferred from separate placebo-controlled trials rather than tested directly.

Weak, from observational data: associations between metformin and lower cancer rates, dementia or longer life; the possible link between semaglutide and optic nerve stroke; reports of mood changes on GLP-1 agonists, which regulators examined without finding a causal link. Observational studies can show patterns but cannot separate the effect of a medicine from the characteristics of the people who take it.

Expert opinion: the sequencing advice in guidelines, including when to add rather than replace, when to prioritize organ protection and how to manage side effects. These recommendations are built on the trials above but involve judgment about trade-offs.

Knowing the grade matters because the viral debate treats every claim as equally certain. The weight and organ-protection findings for semaglutide are among the most robust in diabetes medicine; the suggestion that metformin is useless, or conversely that it is a longevity drug, is not supported at that level.

Common myths about Ozempic and metformin

Viral claims tend to compress a nuanced picture into a slogan. Five of the most common deserve a correction.

Metformin is outdated and doctors only prescribe it out of habit. Guidelines still list metformin as an appropriate first medicine for many adults with type 2 diabetes. What changed is that it is no longer the only acceptable first step, particularly for people with heart or kidney disease.

Ozempic replaces metformin. In most trials and most prescriptions, semaglutide was added to metformin, not substituted for it. Replacement happens for specific reasons such as kidney decline or intolerance.

Metformin causes weight loss like Ozempic does. Metformin’s average effect is about 2 kilograms. Semaglutide’s is several times larger. Anyone promised dramatic weight loss from metformin has been given inaccurate expectations.

Ozempic is dangerous for the thyroid. The warning on the label comes from rodent studies, in which the medicine caused thyroid C-cell tumors. Human data have not shown the same effect, though the medicine is avoided in people with specific inherited thyroid cancer risk. This is a precaution, not a proven harm.

Metformin damages the kidneys. Metformin does not injure kidneys. The caution runs the other way: when kidneys are already weak, the drug can accumulate and raise the risk of lactic acidosis, so prescribers lower or stop it based on kidney tests.

A sixth claim circulates mainly in weight-loss communities: that compounded or imported semaglutide is the same as Ozempic. It is not. Compounded versions were permitted only during a declared shortage, which ended in 2025, were never tested in the outcome trials, and have been linked to dosing errors in regulator reports. They are not for sale as approved medicines and should not be self-administered.

Who tends to be prescribed which, and where off-label questions arise

Clinicians do not pick between these medicines by flipping a coin; they match them to a profile.

Metformin alone is a common starting point for an adult with newly diagnosed type 2 diabetes, an A1c modestly above target, healthy kidneys and no history of heart disease. It is also the only medicine with strong randomised evidence for delaying diabetes in people with prediabetes, although guidelines frame lifestyle change as the first intervention there.

Semaglutide moves to the front when any of the following applies: established cardiovascular disease, chronic kidney disease, heart failure, obesity that is driving the diabetes, or an A1c far enough above target that one medicine is unlikely to be enough. In those cases the injection may be started with metformin or, where metformin is unsuitable, instead of it.

Off-label questions come up constantly. Metformin is often prescribed for polycystic ovary syndrome, a hormonal condition that frequently involves insulin resistance, and for weight gain caused by antipsychotic medicines; randomised trials support modest benefit in both, though neither is an approved indication. GLP-1 agonists are being studied in polycystic ovary syndrome, fatty liver disease, alcohol use disorder and other conditions, with early and mixed results. Ozempic in a person without diabetes who wants to lose weight is technically off-label, since the same molecule carries a separate approval for weight management under a different brand.

In every one of these situations the evidence can inform the conversation, but the decision belongs to the treating clinician, who knows the person’s full history and can monitor for problems. This article is not a basis for requesting a particular medicine or for using one obtained outside a prescription.

Pregnancy is a special case. Metformin has a long record of use in pregnancy under supervision; semaglutide is stopped before a planned pregnancy because of limited safety data, and anyone who may become pregnant should raise this with their prescriber.

When to see a doctor

Most people on either medicine, or both, settle in with nothing worse than a few weeks of stomach upset. Some situations need prompt medical attention, and a few are emergencies.

Seek urgent care, including emergency services if symptoms are severe, for any of the following:

• Severe, persistent abdominal pain, especially pain that spreads to the back, with or without vomiting; this can signal pancreatitis.
• Vomiting or diarrhea that will not stop, inability to keep fluids down, dizziness on standing or very dark urine; dehydration can harm the kidneys.
• Unusual muscle pain, trouble breathing, extreme tiredness, feeling very cold or a slow heartbeat in someone taking metformin; these are warning signs of lactic acidosis.
• Yellowing of the skin or eyes, pain in the upper right abdomen or fever; possible gallbladder problems.
• Sudden vision loss or a dark patch in one eye.
• Symptoms of a serious allergic reaction: swelling of the face, lips or throat, hives, difficulty breathing.
• Blood sugar readings that stay very high or very low, confusion, or shakiness and sweating that does not resolve with sugar.

Book a routine appointment, rather than waiting for the next scheduled review, if you notice a lump or swelling in the neck, difficulty swallowing or persistent hoarseness; new numbness, tingling or memory concerns that could reflect vitamin B12 deficiency on long-term metformin; ongoing nausea or constipation that interferes with eating; or a planned surgery or imaging with contrast dye, since both medicines may need to be paused around procedures.

Never stop, skip or change either medicine on your own, even if a side effect is troubling. Blood sugar can rise quickly when metformin is dropped, and semaglutide has its own guidance for missed doses that only the prescriber or pharmacist should walk through. If you are considering pregnancy, have begun a very low calorie diet or have started any new medicine, mention it at your next contact; each can change how these drugs should be used.

Frequently asked questions

Is Ozempic better than metformin?

For lowering blood sugar and body weight, semaglutide has larger effects in randomised trials, and it has proven heart and kidney benefits that metformin lacks at the same level of evidence. Metformin is simpler, better tolerated by most people and has a sixty-year record. Which is better depends on the goal, the person’s heart and kidney health and their preference about injections, and the choice rests with the prescriber.

Can you take Ozempic and metformin together safely?

Yes. Taking both is one of the most common combinations in type 2 diabetes care, and most semaglutide trials studied it on top of metformin. The medicines work on different parts of the glucose system, so their effects add up, and the pairing carries a low risk of low blood sugar. Digestive side effects can overlap, so report persistent nausea or diarrhea to the prescriber rather than stopping a medicine yourself.

What is the difference between metformin vs semaglutide for weight loss?

Metformin produces an average loss of about 2 kilograms, mainly by preventing weight gain and slightly improving metabolism. Semaglutide reduces appetite directly and produced several kilograms more loss than comparators in diabetes trials, and close to 10 percent of body weight in weight-management trials of the same molecule. Weight tends to return after semaglutide is stopped, so clinicians treat it as long-term therapy.

What should I know before switching from metformin to Ozempic?

A switch is a clinician’s decision, usually made because of declining kidney function, persistent side effects or vitamin B12 problems. For many people the recommendation is to add semaglutide while keeping metformin, since both contribute. Stopping metformin on your own can raise blood sugar within days. If a change is agreed, expect closer glucose checks and a review in the first couple of months when nausea is most likely.

Does metformin have heart benefits like Ozempic?

Probably, but the evidence is weaker. A 1998 trial found fewer heart attacks and deaths among 342 overweight participants on metformin, yet no modern dedicated outcome trial has confirmed the result. Semaglutide, by contrast, reduced major cardiovascular events by 26 percent relative to placebo in a trial of about 3,300 people, which is why guidelines prioritize it for people with existing heart disease.

Why do doctors still prescribe metformin if Ozempic is stronger?

Because strength is not the only criterion. Metformin is a daily tablet, rarely causes low blood sugar, is well tolerated by most people and has been used for decades. Many people reach their blood sugar target on it alone. Guidelines still list it as an appropriate first medicine; what changed is that people with heart or kidney disease are now offered organ-protective medicines like semaglutide whether or not they take metformin.

Which has worse side effects, Ozempic or metformin?

They differ more than they rank. Metformin most often causes diarrhea and nausea that fade within weeks, and long-term use can lower vitamin B12. Semaglutide more often causes nausea and vomiting, particularly as the amount is increased, with rare risks of pancreatitis and gallbladder disease. Serious events are uncommon with either. Persistent or severe symptoms should always be reported to the prescriber.

Does Ozempic protect the kidneys better than metformin?

Semaglutide has direct evidence: the FLOW trial in 2024 showed a 24 percent relative reduction in major kidney outcomes in people with diabetes and chronic kidney disease, and the label was updated in January 2025. Metformin has no equivalent trial and is reduced or stopped when kidney function falls, because it relies on the kidneys for clearance. That difference is a major reason semaglutide is favored in diabetic kidney disease.

Can metformin or Ozempic cause low blood sugar?

On their own, rarely. Neither medicine forces the pancreas to release insulin when glucose is already normal, so hypoglycemia is uncommon with either alone or in combination with each other. The risk rises substantially when either is paired with insulin or a sulfonylurea, which is why prescribers often adjust those medicines when semaglutide is added. Shakiness, sweating and confusion are warning signs that need prompt action.

Is compounded semaglutide the same as Ozempic?

No. Compounded versions were allowed only while regulators listed semaglutide as in shortage, a status that ended in early 2025. They are not approved medicines, were never tested in the trials that established semaglutide’s benefits and have been associated with dosing errors in regulator reports. They are not for self-use, and anyone who has used one should discuss it with a prescriber.

References

• MedlinePlus: Semaglutide Injection
• MedlinePlus: Metformin
• NHS: Metformin
• NHS: Semaglutide

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.